BR9814171A - Vetor de expressão alfavìrus modificado - Google Patents

Vetor de expressão alfavìrus modificado

Info

Publication number
BR9814171A
BR9814171A BR9814171-6A BR9814171A BR9814171A BR 9814171 A BR9814171 A BR 9814171A BR 9814171 A BR9814171 A BR 9814171A BR 9814171 A BR9814171 A BR 9814171A
Authority
BR
Brazil
Prior art keywords
expression vector
modified alphavirus
alphavirus
alphavirus expression
modified
Prior art date
Application number
BR9814171-6A
Other languages
English (en)
Inventor
Mark Parrington
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9814171A publication Critical patent/BR9814171A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)

Abstract

"VETOR DE EXPRESSãO ALFAVìRUS MODIFICADO". Um vetorde expressão alfavírus modificado é proposto em que pelo menosum sítio de gene heterólogo ótimo é introduzido para replicação doalfavírus que pode ser vírus Semliki Forest seguindo administraçãodo vetor para o hodpedeiro.
BR9814171-6A 1997-11-14 1998-11-13 Vetor de expressão alfavìrus modificado BR9814171A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6579397P 1997-11-14 1997-11-14
PCT/CA1998/001065 WO1999025859A1 (en) 1997-11-14 1998-11-13 Alphavirus vectors

Publications (1)

Publication Number Publication Date
BR9814171A true BR9814171A (pt) 2001-10-30

Family

ID=22065156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814171-6A BR9814171A (pt) 1997-11-14 1998-11-13 Vetor de expressão alfavìrus modificado

Country Status (11)

Country Link
EP (1) EP1029069B9 (pt)
JP (1) JP3835669B2 (pt)
AT (1) ATE334217T1 (pt)
AU (1) AU753729B2 (pt)
BR (1) BR9814171A (pt)
CA (1) CA2309835A1 (pt)
DE (1) DE69835369T2 (pt)
DK (1) DK1029069T3 (pt)
ES (1) ES2268797T3 (pt)
PT (1) PT1029069E (pt)
WO (1) WO1999025859A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
AU2001275191A1 (en) 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.
CN1927403B (zh) * 2006-09-29 2010-09-29 张永亮 用于促进仔猪生长、提高仔猪免疫力的药物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9401091D0 (sv) * 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines

Also Published As

Publication number Publication date
ES2268797T3 (es) 2007-03-16
DE69835369T2 (de) 2007-08-23
DE69835369D1 (de) 2006-09-07
EP1029069B9 (en) 2006-12-27
CA2309835A1 (en) 1999-05-27
ATE334217T1 (de) 2006-08-15
AU1139199A (en) 1999-06-07
EP1029069A1 (en) 2000-08-23
WO1999025859A1 (en) 1999-05-27
JP2002508925A (ja) 2002-03-26
DK1029069T3 (da) 2006-12-18
JP3835669B2 (ja) 2006-10-18
PT1029069E (pt) 2006-12-29
EP1029069B1 (en) 2006-07-26
AU753729B2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
ATE338546T1 (de) Effektoren von dipeptidylpeptidase iv
NO950550D0 (no) Sulfonylalkanoylamino-hydroksyetylaminosulfonamider som er nyttige som retrovirale proteaseinhibitorer
DE69630044D1 (de) Viren inaktivierende umhüllungen
DK1037634T3 (da) Oral administrationsform som omfatter en protonpumpeinhibitor (fx pantoprazo)
FI891716A (fi) Hiv-proteasinhibitorer, som aer anvaendbara vid behandling av aids.
WO2002087411A3 (en) Composite scaffolds and methods using same for generating complex tissue grafts
TR200000782T2 (tr) Resorsinol türevleri.
AR051347A1 (es) Protector para punta de aguja
ATE425139T1 (de) Benzamidinderivate
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
BR9814171A (pt) Vetor de expressão alfavìrus modificado
DE60118798D1 (de) Fragmente der intron a von citomegalovirus
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
DK1196433T3 (da) Cykliske peptidderivater som inhibitorer af alpha v, beta-6-integrinet
AU3456893A (en) Pesticidal pre-treatment of wood by microemulsion, micellar or molecular solution
DE69807213D1 (de) Augenschutz gegen chirurgische laserenergie
NO20001415L (no) Farmasøytikum inneholdende vitamin-K-avhengige faktorer
TR200102742T2 (tr) Rezorsinol türevleri
ES2144748T3 (es) Dispositivo y procedimiento para la produccion de material estirado.
BR9913649A (pt) Rede anelar wdm
DK0560900T3 (da) Forebyggelse af synovialadhæsioner
ATE250584T1 (de) Synthese von 5- oder 8-bromoisoquinolin derivaten
CA2339345A1 (en) Optical communications system and method of protecting an optical route
ATE470442T1 (de) Verwendung von gamma-tocotrienol als diuretika
NO20001492L (no) Metode for Õ forhindre misbruk av transdermalt terapeutisk system

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO DE FOLHAS 98 A 99 PUBLICADO NA RPI N.O 1977, DE 25/11/2008. ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.